BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

614 related articles for article (PubMed ID: 28630181)

  • 1.
    Hackel MA; Tsuji M; Yamano Y; Echols R; Karlowsky JA; Sahm DF
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, Against Gram-Negative Bacilli Isolated by Clinical Laboratories in North America and Europe in 2015-2016: SIDERO-WT-2015.
    Karlowsky JA; Hackel MA; Tsuji M; Yamano Y; Echols R; Sahm DF
    Int J Antimicrob Agents; 2019 Apr; 53(4):456-466. PubMed ID: 30471402
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Hackel MA; Tsuji M; Yamano Y; Echols R; Karlowsky JA; Sahm DF
    Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29158270
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Karlowsky JA; Hackel MA; Takemura M; Yamano Y; Echols R; Sahm DF
    Antimicrob Agents Chemother; 2022 Feb; 66(2):e0199021. PubMed ID: 34807757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In Vitro Activity of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacilli Isolated from Patients in Canadian Intensive Care Units.
    Golden AR; Adam HJ; Baxter M; Walkty A; Lagacé-Wiens P; Karlowsky JA; Zhanel GG
    Diagn Microbiol Infect Dis; 2020 May; 97(1):115012. PubMed ID: 32081522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study).
    Kazmierczak KM; Tsuji M; Wise MG; Hackel M; Yamano Y; Echols R; Sahm DF
    Int J Antimicrob Agents; 2019 Feb; 53(2):177-184. PubMed ID: 30395986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
    Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
    Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Shortridge D; Streit JM; Mendes R; Castanheira M
    Microbiol Spectr; 2022 Apr; 10(2):e0271221. PubMed ID: 35262394
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Wise MG; Karlowsky JA; Hackel MA; Takemura M; Yamano Y; Echols R; Sahm DF
    Microb Drug Resist; 2023 Aug; 29(8):360-370. PubMed ID: 37253158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of cefiderocol against high-risk clones of multidrug-resistant Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa and Stenotrophomonas maltophilia.
    Delgado-Valverde M; Conejo MDC; Serrano L; Fernández-Cuenca F; Pascual Á
    J Antimicrob Chemother; 2020 Jul; 75(7):1840-1849. PubMed ID: 32277821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of Humanized Exposures of Cefiderocol (S-649266) against a Diverse Population of Gram-Negative Bacteria in a Murine Thigh Infection Model.
    Monogue ML; Tsuji M; Yamano Y; Echols R; Nicolau DP
    Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28848004
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Nakamura R; Ito-Horiyama T; Takemura M; Toba S; Matsumoto S; Ikehara T; Tsuji M; Sato T; Yamano Y
    Antimicrob Agents Chemother; 2019 Sep; 63(9):. PubMed ID: 31262762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity of cefiderocol (S-649266) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals.
    Falagas ME; Skalidis T; Vardakas KZ; Legakis NJ;
    J Antimicrob Chemother; 2017 Jun; 72(6):1704-1708. PubMed ID: 28369471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activity of Cefiderocol Against
    Iregui A; Khan Z; Landman D; Quale J
    Microb Drug Resist; 2020 Jul; 26(7):722-726. PubMed ID: 32031915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cefiderocol Antimicrobial Susceptibility Testing Considerations: the Achilles' Heel of the Trojan Horse?
    Simner PJ; Patel R
    J Clin Microbiol; 2020 Dec; 59(1):. PubMed ID: 32727829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activity of the novel siderophore cephalosporin, cefiderocol, in Gram-negative pathogens in Europe by site of infection.
    Candel FJ; Santerre Henriksen A; Longshaw C; Yamano Y; Oliver A
    Clin Microbiol Infect; 2022 Mar; 28(3):447.e1-447.e6. PubMed ID: 34298176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reproducibility of broth microdilution MICs for the novel siderophore cephalosporin, cefiderocol, determined using iron-depleted cation-adjusted Mueller-Hinton broth.
    Hackel MA; Tsuji M; Yamano Y; Echols R; Karlowsky JA; Sahm DF
    Diagn Microbiol Infect Dis; 2019 Aug; 94(4):321-325. PubMed ID: 31029489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro antibacterial activities of cefiderocol against Gram-negative clinical strains isolated from China in 2020.
    Kohira N; Hackel MA; Oota M; Takemura M; Hu F; Mizuno H; Sahm DF; Yamano Y
    J Glob Antimicrob Resist; 2023 Mar; 32():181-186. PubMed ID: 36513320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity of cefiderocol against MBL-producing Gram-negative bacteria collected in North America and Europe in five consecutive annual multinational SIDERO-WT surveillance studies (2014-2019).
    Takemura M; Wise MG; Hackel MA; Sahm DF; Yamano Y
    J Antimicrob Chemother; 2023 Aug; 78(8):2019-2027. PubMed ID: 37390312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ARGONAUT-I: Activity of Cefiderocol (S-649266), a Siderophore Cephalosporin, against Gram-Negative Bacteria, Including Carbapenem-Resistant Nonfermenters and
    Jacobs MR; Abdelhamed AM; Good CE; Rhoads DD; Hujer KM; Hujer AM; Domitrovic TN; Rudin SD; Richter SS; van Duin D; Kreiswirth BN; Greco C; Fouts DE; Bonomo RA
    Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30323050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.